tdm-180935
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2022 (NCT05525468)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06363461 | Phase 2 | Apr 13, 2024 | Technoderma Medicines Inc., Therapeutics, Inc. |
| NCT05525468 | Phase 1 | Oct 15, 2022 | Technoderma Medicines Inc., Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Technoderma Medicines Inc. | For profit | 2 | 2 | 2 | 2022 |
| Therapeutics, Inc. | For profit | 2 | 0 | 2 | 2022 |
2 organizations
Page 1 / 1